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Background: Treatment of coronary bifurcation lesions is a complex problem.
Methods: This retrospective single-center study included all consecutive patients with PCI of coronary bifurcations
with stent covering of the side branch (SB) between January 2008 - August 2011.
Two methods were compared: group A represented patients without treatment of SB, group B were patients with
treatment of SB.
Results: Our study group (n = 98) was group A (n = 64, 65.3%) and group B (n = 34, 34.7%). Mean follow-up was
14.1 (group A) vs 12.3 (group B, p = ns) months.
Mean age (years) was 70.3 (group A) vs. 67.0 (group B, p = ns), NSTEMI/STEMI was present in 54.7% (group A) vs.
41,2% (group B, p = ns).
Duration of x-raying (min, group A vs group B) and the amount of contrast medium (ml) were significantly lower in
group A: 18.1 min vs 20.1 min and 225.8 ml vs 307.4 ml (p < 0.05).
Final TIMI flow III inside the MB was reached in 98.4% (group A) vs. 97.1% (group B, p = ns), inside the SB in 84.4%
vs. 94.1% (p = ns).
Target lesion revascularization and target vessel revascularization was seen in 15.9% (group A) vs 32.4% (group B,
p = 0.07), cardiac death in 7.9% (group A) vs 14.7% (group B, p = 0.3).
All MACE revealed were: 23.8% (group A) vs. 47.1% (group B, p = 0.02).
Conclusion: In patients with coronary bifurcations a simpler strategy has a significantly lower MACE.
Trial registration: ClinicalTrials.gov Identifier: NCT01538186
Keywords: Coronary bifurcation lesions, PCI side branch, Simple vs complex strategyBackground
The treatment of coronary bifurcation lesions is still a
point of fervent discussion within the cardiologic com-
munity. Various treatment strategies are used where
simple modalities are differentiated from more complex
strategies.
The more complex treatment modalities include strat-
egies where two stent are used [1-3], whereas a regular* Correspondence: h.vonkorn@new.marienhaus-gmbh.de
1Hetzelstift, Department of Cardiology, Stiftstr. 10, 67434 Neustadt, Germany
Full list of author information is available at the end of the article
© 2013 von Korn et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orone-stent techniques is usually referred to as simple
strategy.
Recent studies [4-7] have shown that a simpler strat-
egy with stenting of only the main branch offers a better
outcome than using two stents.
For this reason the provisional side branch stenting
strategy has emerged as the preferred bifurcation treat-
ment strategy.
We evaluated clinical outcome in a non-randomized
registry of patients with coronary bifurcation lesions
where the side branch had been covered with a stent.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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undergone a PCI of the side branch or not before the
clinical follow-up data was assessed.
Methods
This retrospective observational study collected informa-
tions from all patients who underwent percutaneous
treatment of a de novo coronary bifurcation lesion in a
single German center between January 2008 and August
2011. We included all consecutively presenting patients
with a bifurcation lesion where the side branch had been
covered with a stent placed inside the main branch.
The bifurcation lesions were defined according to the
Medina classification [8].
The study population included male or female patients
older than 18 years of age with a diagnosis of stable an-
gina or silent ischemia. Patients with an acute coronary
syndrome (unstable angina, NSTEMI, STEMI, cardio-
genic shock) were not excluded. Patients with a primary
occlusion of the target vessel and a significant bifur-
cation lesion visible after thrombectomy were also kept
in the patient collective.
The following patients were excluded for methodo-
logical reasons: patients with an in-stent-restenosis, pa-
tients with a therapy using a drug-coated balloon during
the procedure (inside the main branch and/or the side
branch) and patients where the side branch had not
been covered by the stent inside the main branch.
Two different treatment strategies were compared:
group A represented patients with a simple strategy
without any treatment of the side branch (balloon angio-
plasty or stenting). Group B consisted of patients where
the operator treated the side branch (balloon angioplasty
and/or stenting) after or before stenting of the main
branch following the concept of “provisional stenting”.
The demographic data, patient history, coronary risk
factors, lesion location, morphology and procedural
strategy were all documented.
For all patients we used a systematic approach for
treating patients with coronary bifurcation lesions. This
standard was established before the initiation of this
registry. This standard is described in the chapter
“angiographic procedure”.
The study complied with the Declaration of Helsinki
regarding research on humans. All patients provided
their written informed consent. An approval of an ethics
committee was not intended due to the retrospective
nature of our study.
Angiographic procedure
Patients with an acute coronary syndrome were treated
with aspirin 500 mg intravenously and 5000 IE heparin be-
fore admission to our hospital. If the procedure was elective
patients were preloaded with 300 mg clopidogrel.After the procedure, patients were maintained on as-
pirin 100 mg and clopidogrel 75 mg daily. After BMS
implantation clopidogrel was used for 4 weeks, after
DES implantation it was used for 6 months, and in case
of an acute coronary syndrome it was used for 12 months
after the index procedure. Life-long aspirin was pre-
scribed for every patient. Other medications such as ß-
Blockers, angiotensin-converting enzyme inhibitors and
statins were given as indicated.
Use of glycoprotein IIb/IIIa inihibitors was left to the
discretion of the operator. GPIIb/IIIa inhibitors repre-
sents a component of standard care at our hospital
wherever a large thrombus burden is observed.
During the procedure, intravenous heparin was given
to maintain an activated clotting time of > 250 sec. The
radial or femoral approach and 6 F guiding catheters
were used as a matter of routine.
Our standard procedure (established before the start
of this registry) during interventions for bifurcation le-
sions involved the following: (1) wiring of both branches
of the bifurcation lesion, (2) pre-dilatation of the main
branch, (3) stenting of the main branch using a DES or a
BMS, (4) in case of residual stenosis of the side branch
> 50% or a TIMI flow < 2 of the side branch angioplasty
or stenting (“provisional stenting”), (5) final kissing
wherever a side branch had an angioplasty or stenting.
Patients with a diameter of the side branch < 1.5 mm by
eye ball were not included.
If a good result was achieved with a TIMI flow III in
both branches after stenting of only the main branch, or
if there was no visible stenosis of the side branch > 50%
and/or the patient had no angina after removal of the
balloon from the lesion the procedure was terminated
without PCI of the side branch. In this group a really
simple concept was scheduled, with no attempted treat-
ment strategy for the side branch. These patients are
represented in group A.
A defined treatment strategy for the side branch was
prespecified only in patients with the above mentioned
criterias (group B, e.g. TIMI flow reduction or a visible
stenosis of the side branch > 50%).
A final kiss was attempted for every patient where the
side branch was treated, but this was not the case where
patients were treated using the simple strategy (group
A). The first-line therapy in this case was a simultaneous
balloon angioplasty as a “final kissing” PCI. If this strat-
egy could not be accomplished due to failure of balloon
placement, the strategy was switched to a sequential
balloon angioplasty.
Indications for the placement of a side branch stent in
group B included [1] a residual stenosis after balloon
angioplasty > 50%, [2] a flow limiting dissection, [3]
presence of a thrombus or [4] occlusion of the side
branch after balloon angioplasty.
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lesion or a dissection were also permitted. However, no
combination of drug-eluting stents with bare metal
stents was to have been performed.
The balloons were choosen to achieve a balloon-vessel
ratio of ~ 1 after measuring the pre-procedure reference
vessel diameter. We used semi-compliant balloons with
nominal inflation pressures.
Implantation of a drug-eluting stent was preferred in
patients with an acute coronary syndrome (NSTEMI
and STEMI), in patients with long lesions (> 20 mm)
and a small vessel diameter (< 2.5 mm), and in diabetes
mellitus patients.
Angiographic evaluation
Quantitative coronary angiographic (QCA) analysis was
performed using Quantcor QCA (version V2.0 by Pie
Medical Imaging, Maastricht, The Netherlands). QCA
measurements were performed by an independent oper-
ator unaware of the details of the therapy using a dye-
filled catheter as reference.
The minimal lumen diameter (MLD) and percentage
diameter stenosis were measured pre-procedure and
post-procedure. The reference vessel diameter of the
main branch and the side branch was set up where the
diseased segment seems to be unobtrusive.
Clinical definitions and follow-up
Follow-up was carried out either at an office visit, by
looking for data in our local hospital data base or via a
telephone call (with the patient or the home physician)
where the rate of MACE (major adverse cardiac events)
was determined. No scheduled follow-up angiography
was indicated unless it was for patients with significant
coronary lesions for PCI not related to the target bifur-
cation lesion, or patients with evidence of disease pro-
gression due to a new angina pectoris and/or objective
evidence of ischemia.
The follow-up data were defined as either death, myo-
cardial infarction (STEMI and NSTEMI), stent throm-
bosis, CABG or target lesion revascularization (TLR).
All deaths were considered cardiac unless otherwise
documented.
The diagnosis of AMI (STEMI or NSTEMI) both peri-
procedurally and at follow-up required an elevation of
creatine kinase to levels twice those of the upper normal
limit together with a rise in the creatine kinase-MB frac-
tion, an elevation of troponin I and/or new ST-segment
elevations or new Q-waves (ECG). The threshold used
for classifying a positive troponin I test was 0.1 ng/ml.
For CK the manufacturer reported a lower threshold
of > 2.8 μmol/s/l.
Target lesion revascularization (TLR) was defined as
either surgical or percutaneous re-intervention driven by1) significant (> 50%) luminal diameter narrowing either
within the stent or within the 5 mm proximal or distal
to the MB or SB stent edge, 2) stent thrombosis or 3)
TLR-related CABG. This was undertaken in the pres-
ence of either anginal symptoms or objective evidence of
an ischemia including stent thrombosis.
Target vessel revascularization (TVR) was defined as
revascularization by PCI or surgery within the target
vessel encompassing the target lesion including TLR
plus PCI target vessel-non target lesion plus CABG in-
cluding target vessel, not related to the target lesion.
MACE was defined as TVR plus cardiac death.
Classification of a stent thrombosis was based on the
definitions of the Academic Research Consortium (ARC)
regarding definite, probable or possible stent thrombosis
[9]. Stent thromboses were categorized according to the
timing of the event into: intraprocedural thrombosis,
subacute thrombosis (from the end of the procedure to
30 days), and late stent thrombosis (> 30 days).
Statistical analysis
95% confidence intervals for the differences between
both groups are presented in the tables. For binary
variables, odds ratios and their 95% corresponding
confidence intervals were calculated using logistic re-
gressions; for ordinate variables, confidence intervals
referred to the differences between the means.
For a few variables, as indicated in the tables, log
values were taken to accommodate for deviations from
normality where the differences in the resulting means
were tested using t-tests. Statistics from all tests are
reported as 2-sided probability values. All calculations
were performed using Stata 11.
Results
During the period between January 2008 and August
2011 we performed 4070 cardiac catheterizations and
1688 percutaneous interventions (41.5%). Of these, 138
patients had a bifurcation lesion (8.2%).
Patients were excluded from analysis who had an in-
stent-restenosis (n = 8, 0.5%), who had a drug-coated
balloon during PCI (n = 14, 0.8%), and for whom the side
branch had not been covered by the stent (n = 18, 1.1%).
The rest of the population (n = 98, 5.8%) constituted
our study group (see Figure 1).
Baseline characteristics
Baseline and clinical characteristics (including age, sex,
incidence of risk factors) were well matched between the
two groups (see Table 1). The mean age was 70.3 years
(group A) vs. 67.0 years (group B, p = 0.22) and 65.6% of
group A vs. 70.6% of group B (p = 0.62) were male.
The cardiac history of the patients regarding prior PCI




Excluded: Patients with In-
stent-restenosis n= 8, drug-
coated balloon during PCI n= 
14, side branch not covered by a 
stent n= 18
Study population: n= 98 patients
Stentcovering SB without 
PCI of the side branch
n= 64
Stentcovering SB plus 
PCI of the side branch 
n= 34
Figure 1 Patient flow.
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(NSTEMI and STEMI). An acute coronary syndrome
was present in 54.7% (group A) vs 41.2% (group B, see
Table 1).
Lesion characteristics
Details regarding lesion characteristics in the two groups
are reported in Tables 2 and 3. Most of the bifurcations
were located in the region of the LAD/diagonal branchesTable 1 Basic data
Covering SB without
PCI SB (group A)
Age (years: mean, range, standard deviation) 70.3 (40–93; 12.9)
Men (no., percent) 42 (65.6%)
Diabetics (no., percent) 14 (21.9%)
Diabetics, insulin dependent (no., percent) 5 (7.8%)
Hypertension (no., percent) 51 (79.7%)
Persistent smoker (no, percent) 11 (17.2%)
Hypercholesterolemia (no., percent) 28 (43.8%)
Prior PCI (no., percent) 20 (31.3%)
Prior CABG (no., percent) 5 (7.8%)
NSTEMI (no., percent) 21 (32.8%)
STEMI (no., percent) 14 (21.9%)
a Odds ratio; b Difference in means.(59.4% [group A] vs. 55.9% [group B, p = 0.74]), while an
angiographically visible thrombus was present in 15.6%
(group A) vs. 23.5% (group B, p = 0.36). Both groups did
not differ significantly regarding their Medina classifica-
tions (Fisher`s exact test: p = 0.09, see Table 3).
Four patients of group A (6.3%) and three patients
(8.8%) of group B could not be classified regarding their
Medina classification due to a complete occlusion of the
target vessel in patients with STEMI during non-elective
PCI. After restoration of blood flow (thrombectomy or
PCI using an undersized balloon) a significant bifur-
cation lesion was identified.
Procedural details
A thrombectomy was performed before PCI in 9.4%
(group A) vs 11.8% (group B, p = 0.71), GP IIb/IIIa an-
tagonists were used in more patients of group B (24.2%)
than in group A (14.1%), although this difference was
not significant (p = 0.24, see Table 4).
Sequential or parallel final kissing was performed in
n = 14 patients (41.2% in group B). The reasons under-
lying the PCI of the side branch in group B were the
following: stenosis > 50% after covering the side branch
(n = 29, 85.3%), closure of the side branch during the
procedure (n = 2, 5.9%), and visible thrombus after stent
covering (n = 3, 8.8%).
Primary stenting was carried out in 29.7% (group A)
vs 23.5% (group B, p = 0.52). The use of drug-eluting
stents was homogenously distributed in both groups
(56.3% of patients of group A vs. 50.0% of patients of
group B, p = 0.56). In group A, we used a paclitaxel elut-
ing stent in n = 17 (26.6%), a zotarolimus eluting stent
system in n = 12 (18.8%, Resolute Integrity) and a
polymer-free rapamycin eluting stent system (Yukon
choice) in n = 7 (10.9%). In group B a paclitaxel eluting
stent was used in n = 11 (32.4%), a zotarolimus elutingN Covering SB + PCI
SB (group B)
N Difference CI; P
64 67.0 (43–86; 11.8) 34 3.3b (−2.0; 8.6) 0.22
64 24 (70.6%) 34 1.26a (0.51; 3.09) 0.62
64 5 (14.7%) 34 0.62a (0.20; 1.89) 0.40
64 2 (5.9%) 34 0.74a (0.14; 4.02) 0.73
64 25 (73.5%) 34 0.71a (0.27; 1.88) 0.49
64 2 (5.9%) 34 0.30a (0.06; 1.45) 0.13
64 14 (41.2%) 34 0.90a (0.39; 2.09) 0.81
64 11 (32.4%) 34 1.05a (0.43; 2.57) 0.91
64 1 (2.9%) 34 0.35a (0.04; 3.19) 0.36
64 9 (26.5%) 34 0.74a (0.29; 1.86) 0.52
64 5 (14.7) 34 0.62a (0.20; 1.89) 0.40
Table 2 Lesion characteristics
Covering SB without PCI
SB (n = 64, group A)
N Covering SB + PCI SB
(n = 34, group B)
N Difference CI; P
3-vessel disease (no., percent) 19 (29.7%) 64 13 (38.2) 34 1.47a (0.61; 3.52) 0.39
Ejection fraction (%: mean, range,
standard deviation)
53.4% (20–70; 11.5) 64 55.7 (40–65; 8.9) 34 −2.4b (−7.4; 2.7) 0.35
Visible thrombus (no, percent) 10 (15.6%) 64 8 ( 23.5%) 34 1.63 (0.58; 4.62) 0.36
Bifurcation localization: LM (no., percent) 4 (6.3%) 64 1 (2.9%) 34 0.62a (0.06; 6.16) 0.68
Bifurcation localization: LAD/SB (no., percent) 38 (59.4%) 64 19 (55.9%) 34 0.87a (0.37; 2.01) 0.74
Bifurcation localization: LCX/SB (no., percent) 15 (23.4%) 64 9 (26.5%) 34 1.18a (0.45; 3.06) 0.74
Bifurcation localization: RCA/SB (no., percent) 7 (10.9%) 64 5 (14.7%) 34 1.40a (0.41; 4.81) 0.59
a Odds ratio; b Difference in means; c From a Fisher’s exact test.
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rapamycin eluting stent was used in n = 1 (2.9%).
Interestingly, the stent length was longer in group B
(20.7 mm [group B] vs. 17.6 mm [group A]), although
this difference just failed to reach significance (p = 0.05).
The mean stent diameter was 2.7 mm (group A) vs
2.8 mm (group B), a difference which though small was
significant (p = 0.04).
With the simpler strategy, both the amount of contrast
medium (ml) and the duration of x-raying (min) were
both significantly reduced in group A (group A vs group
B, CM usage: 225.8 ml vs. 307.4 ml [p < 0.001] and x ray
time : 18.1 min vs 20.1 min [p = 0.02], see Table 4).Table 3 Medina classification
Covering SB without
PCI SB (group A) *
Covering SB + PCI
SB (group B) *
Medina classification
1-1-1 (no, percent)
12 (20.0%) 2 (6.5%)
Medina classification
1-1-0 (no, percent)
9 (15.0%) 4 (12.9%)
Medina classification
1-0-1 (no, percent)
5 (8.3%) 8 (25.8%)
Medina classification
0-1-1 (no, percent)
1 (1.7%) 3 (9.7%)
Medina classification
1-0-0 (no, percent)
18 (30.0%) 9 (29.0%)
Medina classification
0-1-0 (no, percent)
14 (23.3%) 5 (16.1%)
Medina classification
0-0-1 (no, percent)
1 (1.7%) 0 (0.0%)
Total 60 (100%) 31 (100%)
* Four patients of group A could not be classified due to complete occlusion
of the target vessel in patients with STEMI during non-elective PCI. After
restoration of blood flow (thrombectomy or PCI using a undersized balloon)
a significant bifurcation lesion was identified.
* Three patients of group B could not be classified due to complete occlusion
of the target vessel in patients with STEMI during non-elective PCI. After
restoration of blood flow (thrombectomy or PCI using a undersized balloon)
a significant bifurcation lesion was identified.Procedural results
Final TIMI flow III in the main branch was reached in
98.4% vs. 97.1% (group A vs. group B, p = 0.68) while in
the side branch it was reached in 84.4% vs. 94.1% (group
A vs. group B, p = 0.13, see Table 5).
A final TIMI flow 0 inside the side branch was ob-
served in 7.8% of patients of group A and in no patient
of group B (p = 0.16). No patient from either group had
a final TIMI flow of 0 inside the main branch.
Interestingly a deterioration of TIMI flow to ≥ 1 in the
side branch was present in 6.3% of group A vs 5.9% of
group B (p = 0.94), while an improvement of TIMI flow
inside the side branch was seen in more patients of
group B (29.4%) and in 15.6% of patients of group A,
although this difference was not statistically significant
(p = 0.11, see Table 5).
QCA analysis
The QCA analysis of the main branch revealed no sig-
nificant differences between the groups regarding min-
imal luminal diameter, the percent diameter stenosis or
the lesion length (see Table 6).
The reference diameter of the side branch was signifi-
cantly larger in group B (2.1 mm vs. 1.8 mm for group B
vs group A, p = 0.03), whereas the lesion length was not
different.
The minimal luminal diameter and the percent diam-
eter stenosis of the side branch after the intervention
was significantly larger in patients of group B (1.1 mm/
34.1% [group A] vs. 1.4 mm/22.8% [group b, p = 0.03 for
both modalities]) which can be easily explained by the
fact that a PCI of the side branch was done in this treat-
ment group (see Table 6).
Clinical outcome
Target lesion revascularization occurred in 15.9% of
patients of group A and in 29.4% of patients in group B
(p = 0.12), whereas the incidence of target vessel revascu-
larization was 15.9% (group A) vs. 32.4% (group B,
Table 4 Procedural details
Covering SB without
PCI SB (group A)
N Covering SB + PCI
SB (group B)
N Difference CI; P
Thrombectomy before PCI (no, percent) 6 (9.4%) 64 4 (11.8%) 34 1.29a (0.34; 4.92) 0.71
Primary stenting (no, percent) 19 (29.7%) 64 8 (23.5%) 34 0.73a (0.28; 1.90) 0.52
Stent diameter (mm, mean, range, SD) 2.7 (2.0 – 3.5, 0.31) 64 2.8 (2.0 – 3.5, 0.38) 34 −0.15b (−0.29; -0.01) 0.04
Stent length (mm, mean, range, SD) 17.6 (8.0 – 58.0, 8.8) 64 20.7 (8.0 – 44.0, 8.8) 34 −0.18c (−0.36; -0.00) 0.05
Drug eluting stent (no., percent) 36 (56.3%) 64 17 (50.0%) 34 0.78a (0.34; 1.79) 0.56
Glycoprotein IIB/IIIA antagonists (no., percent) 9 ( 14.1%) 64 8 (24.2%) 34 1.88a (0.65; 5.43) 0.24
Duration of x-ray, min (mean, range, SD) 18.1 (2.7-220; 28.5 ) 64 20.1 (5.8-51.4; 12.2 ) 34 −0.36c (−0.67; -0.06) 0.02
Amount of contrast medium, ml (mean, range, SD) 225.8 (70–640; 104.0) 64 307.4 (180–470; 83.9 ) 34 −81.5a (−122.8; -40.3) <0.001
a Odds ratio; b Difference in means; c Average difference, logged values (for not normally distributed variables).
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stent thrombosis) was observed in either group.
The occurrence of a definite stent thrombosis was 0%
in group A and 8.8% (n = 3) in group B (p = 0.04). Two
of these patients experienced this event, one on day 3
and the other on day 8 after the index procedure under
aspirin plus clopidorel, with these events being suffered
as a subacute thrombosis according to the definition of
the Academic Research Consortium (ARC). One patient
was treated with aspirin monotherapy and suffered an
incident on day 472 after the PCI. As such he was
defined as having suffered a late stent thrombosis.
A (Re)-PCI of the side branch during follow up was
seen in 4.8% (group A) vs 8.8% (group B, p = 0.44,
see Table 7) of the patients.
One very important issue was the analysis of the
nature of cardiac death. Cardiac death was observed in
5 patients from each group (group A = 7.9%, group
B = 14.7%, p = 0.30).
Sudden cardiac death was observed in n = 4 patients
from group A (6.4%) with these events occurring away
from the hospital on day 3, 7, 30 and 61 after the index
procedure: all these patients were under combined
therapy with aspirin plus clopidogrel. These events had
to be classified as a possible stent thrombosis accord-
ing to the ARC definitions [9]. One patient (1.5%) ofTable 5 Procedural results
Covering SB
PCI SB (n = 6
Final TIMI flow III (MB, (no, percent) 63 (98.4%)
Final TIMI flow III (SB, (no, percent) 54 ( 84.4%)
Final TIMI flow 0 (SB) (no, percent) 5 (7.8%)
Final TIMI flow 0 (MB) (no, percent) 0 (0.0%)
Improvement of TIMI flow≥ 1 (MB) during PCI (no, percent) 13 (20.3%)
Improvement of TIMI flow≥ 1 (SB) during PCI (no, percent) 10 (15.6%)
Worsening of TIMI flow≥ 1 (MB) during PCI (no, percent) 0 (0.0%)
Worsening of TIMI flow≥ 1 (SB ) during PCI (no, percent) 4 (6.3%)
a Odds ratio; b Difference in means.group A died in our hospital on day 8 due to progres-
sive heart failure.
All patients from group A who suffered a cardiac
death during follow-up were usually admitted to our
clinic before the index PCI with an acute coronary
syndrome (NSTEMI or STEMI).
The analysis of the patients from group B revealed the
following: sudden cardiac death occurred in one patient
on day 229 (2.9%) under aspirin plus clopidogrel (this
had to be defined as a possible stent thrombosis, see
ARC definitions [9]); one patient (2.9%) had a definite
stent thrombosis (verified during cardiac catheterization)
on day 7 under combined anticoagulation with aspirin
and clopidogrel; one patient (2.9%) died due to progres-
sive heart failure 4 months after PCI; one patient (2.9%)
was admitted to our hospital with a STEMI and resusci-
tation before arrival in our clinic and died after develop-
ment of cardiogenic shock on day 3; one patient (2.9%)
died of unknown cause, the cause could have not been
classified (this was regarded as cardiac death).
Four of these patients were primarily (before the index
PCI) were admitted to the hospital due to an acute cor-
onary syndrome (NSTEMI and STEMI).
An investigation of all MACE revealed a significant
difference in favour of group A (23.8% [group A] vs.
47.1% [group B, p = 0.02].without
4, group A)
Covering SB + PCI
SB (n = 34, group B)
Difference CI; P
33 ( 97.1%) 1.62a (0.16; 16.23) 0.68
32 (94.1%) 3.32a (0.69; 15.94) 0.13
0 (0.0%) 0.078b p = 0.16c
0 (0.0%) 0b n.a.
10 (29.4%) 1.63a (0.63; 4.25) 0.31
10 (29.4%) 2.25a (0.83; 6.11) 0.11
0 (0.0%) 0b n.a.
2 (5.9%) 0.94a (0.16; 5.40) 0.94
Table 6 QCA analysis
Main branch Covering SB without
PCI SB (n = 64, group A)
Covering SB + PCI SB
(n = 34, group B)
Difference CI; P
Minimal luminal diameter, before/after
PCI mm (mean, range, SD)
0.88 (0–1.9; 0.4) 0.82 (0–1.6; 0.4) 0.06a (−0.11; 0.23) 0.46
2.1 (1.1-3.9; 0.5) 2.0 (1.3-3.4; 0.5) 0.00a (−0.21; 0.21) 0.99
% diameter stenosis before/after PCI
(mean, range, SD)
65.4 (48–100; 12.5) 66.3 (49–100; 11.8) −0.9a (−6.5; 4.7) 0.74
16.0 (0–44; 10.5) 19.6 (2–44; 11.1) −3.6a (−8.4; 1.2) 0.14
Reference diameter mm (mean, range, SD) 2.6 (1.3-4.6; 0.6) 2.5 (1.2-4.4; 0.7) 0.07a (−0.23; 0.37) 0.65
Lesion length mm(mean, range, SD) 7.5 (1.5-23.6; 3.5) 9.4 (3.6-31.1; 5.6) −0.20b (−0.42 ; 0.03) 0.08
Side branch Covering SB without PCI SB
(n = 64, group A)
Covering SB + PCI SB
(n = 34, group B)
Difference CI; P
Minimal luminal diameter, before/after
PCI mm (mean, range, SD)
1.2 (0–2.5; 0.5) 1.3 (0.3-2.4; 0.6) −0.08a (−0.33; 0.16) 0.50
1.1 (0–2,3; 0.6) 1.4 (0.7-2.2; 0.4) −0.27a (−0.50; -0.03) 0.03
% diameter stenosis before/after PCI
(mean, range, SD)
34.2 (0–100; 27.0) 44.0 (12–100; 24.7) −9.83a (−21.8; 2.2) 0.11
34.1 (0–100; 25.0) 22.8 (2.9-51.0; 13.5) 11.30a (1.42; 21.17) 0.03
Reference diameter mm (mean, range, SD) 1.8 (0.6-3.3; 0.6) 2.1 (1.3-2.92; 0.5) −0.28a (−0.53; -0.03) 0.03
Lesion length mm(mean, range, SD) 3.0 (0.0-9.2; 2.1) 3.0 (0.3-9.0; 2.1) −0.12b (−0.58; 0.34) 0.61
a Difference in means; b Average difference, logged values (for not normally distributed variables).
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The major findings of the present study were that: 1) the
MACE rate in patients with de novo bifurcation lesions,
stent covering of the side branch and PCI of the side
branch is significantly higher than in patients without
PCI of the side branch, 2) cardiac death tended to showTable 7 Follow-up data (multiple statements were possible)
Covering SB without
PCI SB (group A)
Re-PCI MB, In-segment (no., percent) 5 (7.9%)
Re-PCI SB, In-segment (no., percent) 3 (4.8%)
Definite stent thrombosis ( no., percent) 0 (0%)
CABG related to the target lesion (no., percent) 2 (3.2%)
TLR (no., percent) 10 (15.9%)
PCI target vessel, non-target lesion or CABG
not related to target lesion (no., percent)
0 (0%)
TVR (no., percent) 10 (15.9%)
Cardiac death (no., percent) 5 (7.9%)
All MACE (no., percent) 15 (23.8%)
PCI non-target vessel (no., percent) 6 (9.5%)
Diagnostic cardiac catheterization
without PCI (no., percent)
3 (4.8%)
Non-cardiac death (no., percent) 2 (3.2%)
Lost of follow-up (no., percent) 1 (1.6%)
Follow-up duration, months (mean, range, SD) 14.1 (0–41; 13.1)
a Odds ratio; b Difference in means; c From a Fisher’s exact test.a higher incidence in patients where the side branch was
treated, especially in patients who were initially admitted
with an acute coronary syndrome (NSTEMI or STEMI),
3) the functional results looking at TIMI flow inside the
main branch and the side branch showed no significant
differences between the two therapeutic modalities 4)N Covering SB + PCI
SB (group B)
N Difference CI; P
63 4 (11.8%) 34 1.55a (0.39; 6.19) 0.54
63 3 (8.8%) 34 1.94a (0.37; 10.16) 0.44
63 3 (8.8%) 34 −0.088b 0.041c
63 0 (0%) 34 0.032a 0.54
63 10 (29.4%) 34 2.21a (0.81; 6.01) 0.12
63 1 (2.9%) 34 −0.029b 0.35c
63 11 (32.4%) 34 2.53a (0. 95; 6.80) 0.07
63 5 (14.7%) 34 2.00a (0.54; 7.47) 0.30
63 16 (47.1%) 34 2.84a (1.17; 6.92) 0.02
63 5 (14.7%) 34 1.64a (0.46; 5.82) 0.45
63 2 (5.9%) 34 1.25a (0.20; 7.87) 0.81
63 0 (0%) 34 0.032b 0.54c
64 0 (0%) 34 −0.016b 1.00c
63 12.3 (1–46; 12.8) 34 1.79b (−3.70; 7.27) 0.52
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medium was significantly lower in patients with only
PCI of the main branch.
How can these results be interpreted? The basic data
from the two groups revealed no significant differences,
and there were also no significant differences regarding le-
sion characteristics and the procedural details. Thrombec-
tomy, drug-eluting stents and GPIIb/IIIA antagonists were
all used to an almost identical extent in the two groups.
Interestingly, the stent length in the patients from group
B was slightly longer (20.7 mm vs. 17.6 mm, p = 0.05)
which may have contributed to a higher incidence of
consecutive stent thrombosis and sudden cardiac death.
Consistently with this we found a higher incidence of
definite stent thrombosis amongst group B patients.
In patients with an acute coronary syndrome, a signifi-
cantly higher amount of contrast medium for complex
and long-lasting interventions might trigger pump fail-
ure and cardiogenic shock, a scenario which might ex-
plain the different MACE rates that were observed.
Other procedural artifacts (stent deformation, minimal
disruption with subclinical dissections) for patients
having undergone the complex procedure might also
have contributed to these results since manipulations
with the guide wire had to be carried out for longer.
In patients treated with a complex strategy for cor-
onary artery bifurcation lesions other observers [6]
have noted a higher incidence of cardiac biomarkers
release and a higher level of contrast medium usage.
This may have contributed to a higher incidence of
MACE, in analogy with our own results.
The observed MACE rate in our study group was consist-
ent with other studies including patients with an acute cor-
onary syndrome [1]. In comparison to Adriaenssens et al.
[1] we observed a higher incidence of patients with an acute
coronary syndrome.
Our own group [10] were able to show that a flow-
guided treatment concept for the side branch is not in-
ferior compared to a more complex strategy where the
standard routine was to treat both the main branch and
the side branch. Our actual results showed that this
seems to be the concept of choice for patients undergo-
ing an elective procedure.
In a group of patients with a high incidence of acute
coronary syndromes such as that seen in our study
population, a strictly conservative procedure would ap-
pear to be superior where the primary goal of therapy is
treatment of the main branch. A side branch PCI should
only be indicated in patients where a large side branch
becomes occluded, and only if the amount of contrast
medium used is strictly controlled. Anatomic details of a
residual stenosis > 50% in the side branch like as was our
initial strategy for the therapyof de-novo bifurcation
lesions seems to be less relevant.Clinical implications
We conclude that a simple strategy for patients with de-
novo coronary bifurcation lesions where the side branch
is covered with a stent shows better long-term results
when the side branch is not treated (under the assump-
tion that the treatment strategy was a result of the
angiographic view). This may be an important issue
especially for patients presenting with acute coronary
syndromes.
To the best of our knowledge this study is the first
where harm has been documented as a result of using
complex bifurcation treatment strategies.
Study limitations
In our study we a systematic approach for all patients
presenting with a coronary bifurcation lesion. As well as
all of these patients we also included those presenting
with acute coronary syndromes.
Nevertheless, our database represents a single-center
retrospective analysis that was not randomized, a fact
which also has to be kept in mind. The patients and
operators were not blinded to the different treatment
modalities.
Conclusions
In patients with coronary bifurcation lesions, a simpler
strategy involving no SB-PCI results in a significantly
lower MACE rate compared to a strategy involving
treatment of the SB.
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